On-Label Treatment Persistence Through 24 Months Among Patients with Active Psoriatic Arthritis Initiating Guselkumab or Subcutaneous Tumor Necrosis Factor Inhibitors

Abstract Introduction There is limited prior literature comparing long-term treatment persistence between guselkumab and subcutaneous (SC) tumor necrosis factor inhibitors (TNFi) in biologic-naïve and biologic-experienced patients with active psoriatic arthritis (PsA). This study compared on-label p...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Philip J. Mease, Jessica A. Walsh, Timothy P. Fitzgerald, Soumya D. Chakravarty, Elizabeth Adamson, Bruno Emond, Carmine Rossi, Samuel Schwartzbein, Kana Yokoji, Yuxi Wang, Patrick Lefebvre, Dominic Pilon, Shikha Singla, Joseph F. Merola
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	Adis, Springer Healthcare 2025-11-01
Σειρά:	Rheumatology and Therapy
Θέματα:	Biologic-experienced Biologic-naïve Guselkumab Psoriatic arthritis Subcutaneous tumor necrosis factor inhibitor Treatment persistence
Διαθέσιμο Online:	https://doi.org/10.1007/s40744-025-00804-3
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!